influenza
viru
subtyp
pandem
signific
impact
blood
suppli
due
donor
fear
exposur
viru
hospit
freestand
donor
similarli
pandem
alreadi
led
significantli
reduc
blood
suppli
due
cancel
numer
communitybas
mobil
blood
drive
well
mark
reduct
donor
arriv
schedul
appoint
instanc
result
current
pandem
restrict
congreg
social
distanc
date
unit
state
nearli
american
red
cross
blood
drive
cancel
across
countri
hospitalbas
collect
cancel
due
institut
concern
regard
donor
spread
hospit
patient
vice
versa
cancel
result
fewer
blood
donat
week
blood
american
red
cross
collect
come
drive
held
nonperman
collect
locat
accord
chief
execut
offic
new
york
blood
center
main
blood
supplier
new
york
citi
around
incom
blood
suppli
interrupt
week
march
school
busi
religi
institut
close
due
coronaviru
moreov
number
elig
donor
cours
pandem
inevit
decreas
due
increas
number
individu
infect
selfquarantin
exposur
infect
person
person
investig
addit
blood
collect
facil
put
addit
screen
criteria
place
declin
donor
thehistori
travel
infect
hot
spot
preced
day
time
larg
proport
popul
travel
school
spring
break
final
older
person
often
repres
reliabl
donor
pool
also
appar
among
vulner
pandem
default
respons
reduc
blood
suppli
limit
capac
health
care
facil
suspens
elect
surgic
procedur
regardless
lack
uniform
definit
elect
yet
blood
util
urgent
emerg
intervent
actual
repres
greater
demand
blood
suppli
like
remain
unchang
like
true
chronic
transfusiondepend
patient
includ
malign
hematolog
condit
eg
sickl
cell
thalassemia
myelodysplast
syndrom
chemotherapyinduc
anemia
case
cancel
elect
surgeri
may
permit
diseas
progress
result
complex
urgent
situat
pandem
progress
call
blood
center
donor
suffici
allevi
problem
context
pandem
pressur
blood
collect
facil
hospit
transfus
medicin
servic
staff
also
increas
staff
member
requir
selfisol
selfquarantin
becom
ill
addit
effort
continu
standard
blood
donor
recruit
divert
part
grow
initi
manufactur
convalesc
plasma
patient
recov
treatment
option
remain
investig
limit
basi
current
major
sourc
demand
blood
donat
rapidli
evolv
natur
pandem
might
quickli
chang
landscap
creat
substanti
new
demand
also
note
suppli
chain
often
affect
travel
restrict
factori
close
decreas
manufactur
output
may
turn
affect
abil
blood
servic
maintain
test
product
facil
time
increas
need
anoth
remot
signific
issu
possibl
viru
transmiss
via
donat
blood
stage
pandem
expect
consider
percentag
popul
unknowingli
infect
includ
young
blood
donor
popul
asymptomat
case
common
absenc
nucleic
acid
test
nat
blood
donor
screen
exclud
albeit
theoret
time
possibl
transmiss
via
blood
transfus
donat
blood
may
thu
face
signific
unknown
futur
studi
elucid
true
risk
transfusiontransmit
reason
medic
commun
must
adopt
solut
continu
andor
resum
care
patient
popul
thu
immedi
global
implement
patientbloodmanag
pbm
pbm
defin
evidencebas
bundl
care
optim
medic
surgic
patient
outcom
clinic
manag
preserv
patient
blood
wwwifpbmorg
altern
time
applic
evidencebas
medic
concept
design
maintain
hemoglobin
concentr
optim
hemostasi
minim
blood
loss
effort
improv
patient
outcom
wwwsabmorg
nation
blood
author
australia
evidencebas
pbm
guidelin
exhaust
systemat
review
literatur
attend
rigor
methodolog
develop
recommend
practic
point
expert
opinion
point
modul
contain
recommend
practic
point
expert
opinion
point
pbm
toolbox
tabl
summar
practic
concept
numer
larg
observ
sever
random
control
demonstr
significantli
improv
patient
outcom
pbm
substanti
reduc
blood
util
concept
pbm
proactiv
focus
patient
need
well
condit
usual
lead
transfus
name
blood
loss
coagulopathi
platelet
dysfunct
anemia
pbm
shift
focu
reactiv
transfus
patient
allogen
blood
compon
prevent
measur
optim
manag
patient
blood
pbm
concept
endors
world
health
assembl
resolut
recommend
standard
care
european
commiss
recent
action
framework
advanc
univers
access
safe
effect
qualityassur
blood
compon
effect
implement
pbm
list
despit
strong
recommend
avail
evid
demonstr
pbm
model
option
rather
necess
practic
chang
still
lag
far
behind
furthermor
expert
consensu
demonstr
pbm
model
improv
clinic
outcom
increas
patient
safeti
reduc
cost
hospit
organ
pbm
program
far
total
billion
peopl
world
popul
affect
anemia
repres
preval
impair
case
iron
defici
caus
howev
preval
anemia
hospit
patient
significantli
higher
gener
popul
reach
specif
surgic
anemia
associ
increas
blood
util
wors
patient
outcom
increas
morbid
mortal
surgic
medic
patient
prevent
earli
diagnosi
prompt
treatment
direct
etiolog
anemia
decreas
blood
util
improv
patient
outcom
iron
defici
without
anemia
common
associ
increas
mortal
cardiac
may
treat
oral
intraven
iron
supplement
oral
therapi
often
poorli
toler
slower
onset
action
intraven
iron
insuffici
correct
iron
defici
presenc
ongo
bleed
intraven
iron
therapi
prefer
intoler
oral
therapi
sever
anemia
ie
hemoglobin
gdl
plan
surgic
procedur
obstetr
deliveri
within
week
mani
formul
allow
rapid
safe
complet
correct
iron
defici
women
adolesc
girl
present
obstetr
care
menorrhagia
emerg
medicin
depart
sever
iron
defici
must
offer
intraven
iron
mitig
risk
prevent
anemia
relat
nutrit
defici
folat
vitamin
may
mani
case
correct
oral
therapi
folat
vitamin
typic
dose
mg
daili
erythropoiesisstimul
agent
esa
exogen
form
erythropoietin
includ
epoetin
alfa
longeract
darbepoetin
alfa
emerg
esa
may
usedto
stimul
erythropoiesi
esa
often
use
longterm
manag
anemia
patient
chronic
kidney
diseas
chemotherapyinduc
bone
marrow
suppress
increas
expans
shortterm
use
preoper
anemia
particularli
anemia
deem
secondari
anemia
preoper
patient
critic
ill
esa
util
either
unit
weekli
intens
care
unit
icu
preoper
period
result
higher
hemoglobin
concentr
reduc
transfus
coagulopathi
promptli
recogn
correct
perpetu
cycl
bleed
blood
util
patient
sever
evidencebas
strategi
avail
appropri
manag
coagulopathi
pointofcar
viscoelast
test
includ
thromboelastographi
rotat
thromboelastometri
facilit
near
realtim
identif
coagul
abnorm
therebi
allow
rapid
target
correct
impair
pathway
rather
reli
unguid
administr
plasma
transfus
therapi
often
avoid
altogeth
util
clot
factor
prothrombin
complex
concentr
fibrinogen
concentr
addit
transfusionspar
effect
clot
factor
also
decreas
risk
oftransfusionrel
complic
transfusionrel
acut
lung
injuri
trali
transfusionassoci
circulatori
overload
taco
lead
caus
transfusionrel
morbid
antifibrinolyt
agent
includ
tranexam
acid
epsilon
aminocapro
acid
wide
avail
inexpens
highli
effect
safe
pharmacolog
agent
may
usedto
stabil
clot
format
prevent
hyperfibrinolysi
use
agent
consist
associ
bleed
reduct
transfus
reduct
improv
outcom
across
numer
surgic
procedur
trauma
numer
modal
avail
periop
blood
includ
avoid
hemodilut
restrict
transfus
strategi
type
allogen
blood
optim
physiolog
respons
anemia
earli
treatment
coagulopathi
use
topic
hemostat
agent
cell
salvag
involv
collect
patient
blood
loss
filter
wash
ensur
remov
impur
direct
return
autolog
compon
patient
associ
reduct
allogen
blood
compon
util
therefor
recommend
procedur
moderatetolarg
volum
blood
acut
normovolem
hemodilut
anh
process
control
volum
patient
blood
remov
surgic
insult
follow
replac
crystalloid
adult
result
less
red
blood
cell
loss
surgic
procedur
allow
reinfus
autolog
blood
rich
red
blood
cell
platelet
clot
factor
need
intraop
anh
provid
autolog
fresh
whole
blood
sequest
deliv
red
bloodcel
plasma
platelet
need
use
like
benefici
procedur
signific
blood
loss
anh
thu
consid
casebycas
basi
medic
surgic
patient
also
essenti
limit
iatrogen
blood
loss
often
occur
diagnost
phlebotomi
method
reduc
iatrogen
blood
loss
includ
minim
unnecessari
blood
sampl
use
pediatr
small
vacuum
blood
draw
allow
test
hospit
autom
chemistri
line
employ
closedloop
sampl
bleed
postop
postobstetr
deliveri
arecommon
areassoci
increas
resourc
util
wors
clinic
outcom
therefor
essenti
patient
receiv
serial
evalu
bleed
includ
assess
drain
output
frequent
monitor
hemodynam
statu
physic
examin
patient
suspect
bleed
coagulopathi
pointofcar
viscoelast
test
hemoglobin
assess
may
use
rapid
identif
bleed
coagul
abnorm
well
rapid
employ
surgic
intervent
radiolog
intervent
immedi
achiev
sourc
control
import
involv
key
stakehold
decisionmak
process
let
know
wellb
health
love
one
areat
center
comprehens
effort
patient
chronic
transfus
need
prompt
frequent
messag
reassur
effort
deploy
maintain
access
transfus
difficult
decis
need
made
patient
requir
massiv
transfus
traumat
injuri
gastrointestin
bleed
cardiovascular
poor
chanc
short
longterm
surviv
transfus
multipl
unit
blood
compon
singl
patient
associ
high
morbid
mortal
massiv
transfus
could
also
compromis
transfus
support
mani
patient
face
substanti
challeng
pandem
left
one
worldwid
safe
unaffect
medic
urgent
need
provid
optim
compassion
care
use
everi
modal
conserv
resourc
appropri
resourc
conserv
allow
better
alloc
patient
absolut
need
author
call
action
document
repres
divers
background
specialti
yet
come
togeth
cohes
messag
underscor
essenti
role
patient
blood
manag
manag
pandem
urg
implement
practic
commonsens
principl
pbm
multiprofession
multimod
approach
manuscript
prepar
present
behalf
intern
foundat
patient
blood
manag
ifpbm
societi
advanc
blood
manag
sabm
work
group
member
work
group
also
author
manuscript
includ
aryeh
shander
susan
goobi
matti
aapro
elvira
bisb
melissa
cush
wayn
b
dyer
jochen
erhard
shannon
farmer
bernd
froessler
han
gombotz
irwin
gross
thorsten
haa
jeffrey
hamdorf
jame
p
isbist
hongwn
ji
youngwoo
kim
sigismond
lasocki
michael
f
leahi
jeong
jae
lee
jen
meier
sherri
ozawa
marco
pavesi
donat
r
spahn
bruce
spiess
kevin
trentino
christoph
zener
axel
hofmann
ifpbm
aryeh
shander
susan
mari
goobi
melissa
cush
steven
frank
irwin
gross
nicol
r
guinn
daryl
j
kor
sherri
ozawa
bruce
spiess
axel
hofmann
sabm
name
aryeh
shander
md
contribut
author
help
initi
call
action
develop
first
draft
anemia
blood
loss
coagulopathi
abc
toolbox
patient
blood
manag
pbm
critic
revis
draft
approv
final
version
publish
conflict
interest
shander
consult
masimo
corp
vifor
octapharma
csl
behr
therapeut
daiichi
grifol
baxter
speaker
merck
name
susan
goobi
md
contribut
author
help
develop
first
draft
abc
toolbox
pbm
critic
revis
draft
approv
final
version
publish
conflict
interest
goobi
pbm
execut
section
editor
anesthesia
analgesia
serv
scientif
data
safeti
monitor
chair
octapharma
trial
sponsor
speaker
masimo
scientif
advisori
consult
haemonet
name
matthew
warner
md
contribut
author
help
develop
first
draft
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
matti
aapro
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
aapro
receiv
consult
fee
vifor
pharma
name
elvira
bisb
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
e
bisb
receiv
honoraria
lectur
andor
travel
support
vifor
pharma
ompharma
takeda
sysmex
zambon
name
angel
perezcalatayud
md
contribut
author
help
identifi
addit
refer
critic
revis
draft
approv
final
version
publish
conflict
interest
perezcalatayud
receiv
honoraria
lfb
octapharma
ilwerfen
cheetah
medic
baxter
vifor
takeda
name
jeanni
callum
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
j
callum
receiv
research
support
canadian
blood
servic
canadian
institut
health
research
csl
behr
octapharma
name
melissa
cush
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
cush
receiv
honoraria
ceru
octapharma
consult
name
wayn
b
dyer
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
w
b
dyer
employe
australian
red
cross
lifeblood
name
jochen
erhard
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
j
erhard
receiv
honoraria
lectur
vifor
name
david
faraoni
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
shannon
farmer
mb
contribut
author
help
develop
abc
toolbox
pbm
critic
revis
draft
approv
final
version
publish
conflict
interest
farmer
receiv
travel
meet
support
nation
blood
author
australia
name
tatyana
fedorova
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
steven
frank
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
frank
scientif
advisori
board
haemonet
medtron
baxter
name
bernd
froessler
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
b
froessler
receiv
financi
support
give
lectur
undertak
research
attend
scientif
advisori
board
undertak
consult
new
south
wale
depart
health
south
australia
depart
health
australian
red
cross
blood
servic
australian
nation
blood
author
vifor
pharma
ltd
switzerland
pharmacosmo
denmark
pfizer
australia
csl
behr
australia
name
han
gombotz
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
irwin
gross
md
contribut
author
help
identifi
addit
refer
critic
revis
draft
approv
final
version
publish
conflict
interest
gross
receiv
consult
fee
accumen
inc
phoenix
arizona
role
senior
medic
advisor
name
nicol
r
guinn
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
thorsten
haa
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
haa
consult
octapharma
name
jeffrey
hamdorf
md
phd
contribut
author
help
develop
abc
toolbox
pbm
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
jame
p
isbist
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
mazyar
javidroozi
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
javidroozi
consult
sabm
gauss
surgic
name
hongwen
ji
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
youngwoo
kim
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
daryl
j
kor
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
j
kor
scientif
advisori
board
terumo
medic
corpor
consult
instrument
laboratori
uptod
consult
nation
institut
health
nih
receiv
grant
fund
nih
name
johann
kurz
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
sigismond
lasocki
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
lasocki
consult
vifor
pharma
sponsor
speaker
masimo
vifor
pfizer
scientif
advisori
consult
isep
investig
coordin
hip
fractur
iron
tranexam
acid
hifit
studi
pharmcosmo
give
iron
free
name
michael
f
leahi
mbchb
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
cheukkwong
lee
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
jeong
jae
lee
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
vernon
louw
mbchb
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
v
louw
receiv
honoraria
andor
travel
support
andor
grant
fund
follow
acino
austel
novarti
oncolog
pharmacosmo
takeda
vifor
serv
nonexecut
director
board
western
cape
blood
servic
name
jen
meier
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
anna
mezzacasa
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
anna
mezzacasa
employe
vifor
pharma
name
manuel
munoz
md
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
munoz
receiv
honoraria
consult
andor
lectur
pharmacosmo
pharmanutra
vifor
pharma
zambon
celgen
name
sherri
ozawa
rn
contribut
author
help
develop
abc
toolbox
pbm
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
marco
pavesi
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
nina
shander
bs
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
donat
r
spahn
md
contribut
author
help
identifi
addit
refer
critic
revis
draft
approv
final
version
publish
conflict
interest
r
spahn
receiv
honoraria
travel
support
consult
lectur
danub
univers
krem
krem
der
donau
austria
european
societi
anesthesiolog
brussel
belgium
bayer
pharma
ag
berlin
germani
b
braun
melsungen
ag
melsungen
germani
csl
behr
gmbh
hattersheim
main
germani
bern
switzerland
daiichi
sankyo
ag
thalwil
switzerland
haemonet
braintre
massachusett
instrument
laboratori
werfen
bedford
massachusett
lfb
courtaboeuf
cedex
franc
octapharma
ag
lachen
switzerland
paion
deutschland
gmbh
aachen
germani
pharmacosmo
holbaek
denmark
pierr
fabr
pharma
allschwil
switzerland
vifor
pharma
munich
germani
vienna
austria
switzerland
vifor
intern
ag
st
gallen
switzerland
zuellig
pharma
hold
singapor
academ
depart
receiv
grant
support
swiss
nation
scienc
foundat
bern
switzerland
swiss
societi
anesthesiolog
reanim
sgar
bern
switzerland
swiss
foundat
anesthesia
research
zurich
switzerland
vifor
sa
switzerland
cochair
abctrauma
faculti
sponsor
unrestrict
educ
grant
novo
nordisk
health
care
ag
zurich
switzerland
csl
behr
gmbh
marburg
germani
lfb
courtaboeuf
cedex
franc
octapharma
ag
lachen
switzerland
name
bruce
spiess
md
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
b
spiess
paid
consult
hemoson
name
jacki
thomson
mbchb
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
kevin
trentino
mph
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
christoph
zenger
phd
contribut
author
help
critic
revis
draft
approv
final
version
publish
conflict
interest
none
name
axel
hofmann
drrermed
contribut
author
help
initi
call
action
develop
first
draft
abc
toolbox
pbm
critic
revis
draft
approv
final
version
publish
conflict
interest
hofmann
receiv
honoraria
andor
travel
support
ilwerfen
celgen
therapeut
vifor
takeda
manuscript
handl
thoma
r
vetter
md
mph
